Member Directory

AdAlta Limited

Member Contact: Tim Oldham

Position: CEO and Managing Director

Industry: Biotech & Pharmaceuticals

Company Profile:

AdAlta Limited is a Melbourne, Australia-based clinical stage drug development company. The company is focused on using its proprietary i-body technology platform to generate a new class of protein therapeutics with the affinity and specificity of monoclonal antibodies and the beneficial stability features of small molecules. AdAlta is utilising the power of its i-body technology platform to develop an internal pipeline of i-bodies enabled drugs and is also actively establishing co-development partnerships with other biopharmaceutical companies. AdAlta is initially focused on treating fibrotic disease and is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. Phase I clinical trials commenced in mid-2020.

Home

News & opinion

Events

CLICK HERE TO SUBSCRIBE TO OUR NEWSLETTER

BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria: the Bunurong, Gunaikurnai and Wurundjeri peoples, on which the BioMelbourne Network and our Victorian members work, and as well as the lands and waters of our members further afield. We pay respect to their Elders past and present. As Australia’s first scientists, we acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.

We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.